Damora Therapeutics (DMRA)
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’...
- Open
- 29.890
- High
- 30.780
- Low
- 29.140
- Prev. Close
- 29.540
- Volume
- 234.88K
- Turnover
- 7.07M
- Avg Price
- 30.096
- Bid/Ask Ratio
- --
- Amplitude
- 5.55%
- 52wk High
- 38.325
- Volume Ratio
- 0.44
- Turnover Ratio
- 0.58%
Damora Therapeutics Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$44.6747.12%
Forecast & RatingStrong buy
10analysts
- Strong buy90.00%
- Buy10.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 15 hours ago
Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy
- PUBT · 1 day ago, 03:39 PM
Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms
- Unusual Whales · 1 day ago, 03:07 PM
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- PUBT · 1 day ago, 03:04 PM
Damora Q2 net loss widens to $31.17 million
- PUBT · Aug 5 at 07:03 AM
Damora Therapeutics starts Phase 1/1b CLARITY-101 trial of DMR-001 in mutant CALR-driven ET, myelofibrosis
- PUBT · Aug 3 at 03:01 PM
Damora Therapeutics grants 451,000 inducement stock options at $28.99 per share
